Reference : Breaking the Relentless Course of Hallopeau's Acrodermatitis by Dapsone
Scientific journals : Article
Human health sciences : Dermatology
Breaking the Relentless Course of Hallopeau's Acrodermatitis by Dapsone
Nikkels, Arjen mailto [Université de Liège - ULiège > > Dermatologie >]
Tassoudji, Nazli [Université de Liège - ULiège > > Dermatologie >]
Pierard, Gérald mailto [Université de Liège - ULiège > > Dermatopathologie >]
European Journal of Dermatology
John Libbey Eurotext
Yes (verified by ORBi)
[en] We report the case of a 74-year-old man who suffered for four years from recurrent generalized pustular eruptions associated with acrodermatitis continua of Hallopeau (ACH). Initial therapy using topical corticosteroids, tars and PUVA failed to improve the acral lesions. The disease was also unresponsive to systemic therapy using corticosteroids, methotrexate, etretinate, acitretine and cyclosporin A. Serious side-effects were experienced with these drugs. A marked improvement of the generalized pustules was observed under treatment combining etretinate and methotrexate, without having any effect on the acropustulosis. During hospitalization, a topical tar therapy cleared the pustular rash. Again no effect was observed on the acral lesions. Disulone (DDS) therapy, initiated at a dose of 200 mg/day, completely cleared ACH after 4 weeks. The disease relapsed when the dose was reduced to 100 mg/day. Increasing the DDS to 150 mg/day was rapidly followed by a new clearance of the acral lesions. After a 3-month treatment, the patient has remained lesion free and no DDS-related side-effects have occurred. In conclusion, sulfones may be considered as an alternative therapeutic option in drug-resistant ACH.

File(s) associated to this reference

Fulltext file(s):

Restricted access
Breaking the relentless course of Hallopeau's acrodermatitis by dapsone.pdfPublisher postprint780.69 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.